Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.
Amin AD, Rajan SS, Liang WS, Pongtornpipat P, Groysman MJ, Tapia EO, Peters TL, Cuyugan L, Adkins J, Rimsza LM, Lussier YA, Puvvada SD, Schatz JH.
Amin AD, et al. Among authors: schatz jh.
Cancer Res. 2015 Jul 15;75(14):2916-27. doi: 10.1158/0008-5472.CAN-14-3437. Epub 2015 May 27.
Cancer Res. 2015.
PMID: 26018086
Free PMC article.